An expert consensus to define how higher standards of equitable care for von Willebrand disease can be achieved in the UK and Republic of Ireland.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
May 2023
Historique:
revised: 27 01 2023
received: 22 11 2022
accepted: 09 02 2023
medline: 18 5 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder. However, recognition of the disease by both the public and healthcare professionals lags behind that of other bleeding disorders, leading to delays in diagnosis and treatment for patients. Updated national guidelines are needed to highlight an appropriate pathway for managing VWD patients in a timelier manner. To identify ways in which care for VWD can be achieved on a more equitable basis. Using a modified Delphi approach, a panel of VWD experts developed 29 statements across five key themes. These were used to form an online survey that was distributed to healthcare professionals involved in VWD care across the UK and Republic of Ireland (ROI). Stopping criteria comprised 50 responses received, a 3-month window for response (February-April 2022) and 90% of statements passing consensus threshold. Threshold for consensus for each statement was agreed at 75%. A total of 66 responses were analysed with 29/29 statements achieving consensus of which 27 attained ≥90% agreement. From the high degree of consensus, eight recommendations were derived regarding how detection and management of VWD can be improved to provide equity of care between men and women. Implementation of these eight recommendations across the VWD pathway has the potential to raise the standard of care for patients in the UK and ROI by reducing delays to diagnosis and treatment initiation.

Identifiants

pubmed: 36877609
doi: 10.1111/hae.14765
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

819-826

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd.

Références

James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. doi:10.1182/bloodadvances.2020003265
Franchini M, Seidizadeh O, Mannucci PM. Prophylactic management of patients with von Willebrand disease. Ther Adv Hematol. 2021;12:20406207211064064. doi:10.1177/20406207211064064
Fogarty H, Doherty D, O'Donnell JS. New developments in von Willebrand disease. Br J Haematol. 2020;191(3):329-339. doi:10.1111/bjh.16681
Irish Haemophilia Society. Von Willebrand Disorder. 2020. Accessed October 1, 2022. https://haemophilia.ie/app/uploads/2020/10/vWD-New-Edition-2020.pdf
NICE. Heavy Menstrual Bleeding: Quality Standard 47. Updated 2020. Accessed October 1, 2022. https://www.nice.org.uk/guidance/qs47
Spradbrow J, Letourneau S, Grabell J, et al. Bleeding assessment tools to predict von Willebrand disease: utility of individual bleeding symptoms. Res Pract Thromb Haemost. 2019;4(1):92-99. doi:10.1002/rth2.12256
NICE. Heavy menstrual bleeding: assessment and management (NG88). Updated 2021. Accessed October 1, 2022. https://www.nice.org.uk/guidance/ng88
Jacobson AE, Vesely SK, Koch T, et al. Von Willebrand Disease Screening in Women Undergoing Hysterectomy for Heavy Menstrual Bleeding. Blood. 2017;130(1):674. doi:10.1182/blood.V130.Suppl_1.674.674
Lavin M, Aguila S, Dalton N, et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784-1791. doi:10.1182/bloodadvances.2018017418
Sanigorska A, Chaplin S, Holland M, Khair K, Pollard D. The lived experience of women with a bleeding disorder: a systematic review. Res Pract Thromb Haemost. 2022;6(1):e12652. doi:10.1002/rth2.12652
NICE. Scope to inform clinical evidence review of: Vonicog alfa for the treatment and prevention of bleeding in people with von Willebrand disease. NICE ID018 /NHS England Policy URN 1709 Final November 2018. Accessed October 5, 2022. https://www.nice.org.uk/Media/Default/About/what-we-do/Commissioning-Support-Programme/Vonicog-alfa-final-scope.pdf
Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost. 2020;5(1):51-54. doi:10.1002/rth2.12468
van Galen KPM, Lavin M, Skouw-Rasmussen N, et al. Clinical management of woman with bleeding disorders: a survey among European haemophilia treatment centres. Haemophilia. 2020;26(04):657-662. doi:101111/hae.14043
van Galen KPM, Lavin M, Skouw-Rasmussen N, et al. European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of care for women and girls with inherited bleeding disorders. Haemophilia. 2021;27(5):837-847. doi:10.1111/hae.14379
Meijer K, van Heerde W, Gomez K. Diagnosis of rare bleeding disorders. Haemophilia. 2021(3):60-65. doi:10.1111/hae/14049
Rodeghiero F, Tosetto A, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063-2065. doi:10.1111/j.1538-7836.2010.03975.x
RCGP. 15-minute minimum consultations, continuity of care through ‘micro-teams’, and an end to isolated working: this is the future of general practice. 2019. Accessed October 6, 2022. https://www.rcgp.org.uk/getmedia/ffof6ea4-bce1-4d4e-befc-d8337db06d0e/RCGP-fit-for-the-future-report-may-2019.pdf
Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost. 2008;6(12):2062-2066. doi:10.1111/j.1538-7836.2008.03182.x
Deforest M, Grabell J, Albert S, et al. Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia. 2015;21(5):e384-8. doi:10.1111/hae.12747
Yeung K, McGrath C, Howse K, James P. Management of patients with elevated Self-BAT scores or other bleeding symptoms: updated overview for primary care practitioners. Can Fam Physician. 2022;68(7):494-499. doi:10.46747/cfp.6807494
Punt MC, Blaauwgeers MW, Timmer MA, et al. Reliability and feasibility of the self-administered ISTH-Bleeding Assessment Tool. TH Open. 2019;3(4):e350-e355. doi:10.1055/s-0039-3400483
Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol. 2008;140(5):496-504. doi:10.1111/j.1365-2141.2007.06968.x
Alzahrani A, Othman N, Bin-Ali T, et al. Routine preoperative coagulation tests in children undergoing elective surgery or invasive procedures: are they still necessary. Clin Med Insights Blood Disord. 2019;12. doi:10.1177/1179545X188211581179545X18821158
James PD. Women and bleeding disorders: diagnostic challenges. Hematology Am Soc Hematol Educ Program. 2020;2020(1):547-552. doi:10.1182/hematology.2020000140
Data and Statistics on von Willebrand Disease. Accessed October 9, 2020. https://www.cdc.gov/ncbddd/VWD/data.html
Atiq F, Saes JL, Punt MC, et al. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine. 2021;32:100726. doi:10.1016/j.eclinm.2021.100726
Noone D, Skouw-Rasmussen N, Lavin M, et al. Barriers and challenges faced by women with congenital bleeding disorders in Europe: results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia. 2019;25:468-474. doi:10.1111/hae.13722
Xu Y, Deforest M, Grabell J, et al. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017;23:115-121. doi:10.1111/hae.13062
Von Mackensen S, Federici A, Quality of life assessment in patients with von Willebrand's disease: development of a first disease-specific instrument (VWD-QOL). Poster presentation at the annual congress of the Society of Thrombosis and Haemostasis Research, Dresden, 21-25 February 2007, P126. 2007.
Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264

Auteurs

Mike Laffan (M)

Centre for Haematology, Imperial College London, London, UK.

Gary Benson (G)

NI Haemophilia Comprehensive Care Centre, Belfast City Hospital, Belfast, UK.

Cathy Farrelly (C)

Liverpool Hospital, Liverpool, UK.

Keith Gomez (K)

Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.

April Jones (A)

Royal Victoria Infirmary, Newcastle, UK.

Rhona Maclean (R)

Sheffield Royal Hallamshire, Sheffield, UK.

James O'Donnell (J)

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, UK.
National Coagulation Centre, St James's Hospital, Dublin, UK.

Michelle Lavin (M)

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, UK.
National Coagulation Centre, St James's Hospital, Dublin, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH